Metsera (MTSR) Registration Filing summary

Company overview and business model

• Clinical-stage biotech developing next-generation injectable and oral NuSH analog peptides for obesity, overweight, and related conditions.

• Proprietary platforms: MINT peptide library, HALO half-life extension, and MOMENTUM oral delivery.

• Lead candidates: MET-097i (monthly injectable GLP-1 RA), MET-233i (injectable amylin analog), MET-2240 (oral GLP-1 RA), and multiple preclinical programs.

• Focus on addressing limitations of current therapies: dosing frequency, titration, tolerability, efficacy, and scalability.

• Targeting large global markets, initially U.S. and Europe, with plans for scalable manufacturing.

Financial performance and metrics

• Net loss of $47.2M for 2023 and $156.3M for the nine months ended September 30, 2024; accumulated deficit of $204.3M as of September 30, 2024.

• Cash and cash equivalents of $187.6M as of September 30, 2024; pro forma as adjusted cash post-IPO estimated at $653.3M.

• Operating expenses driven by R&D ramp-up, clinical trials, and general/admin costs.

• No revenue to date; operations funded by equity financings, including $215M Series B in November 2024.

Use of proceeds and capital allocation

• Estimated net IPO proceeds of $250.8M (at $16/share midpoint), or $289.1M if underwriters' option exercised.

• Proceeds to fund Phase 3 clinical trial of MET-097i through topline results and related milestones; remainder for working capital and general corporate purposes.

• Existing cash and IPO proceeds expected to fund operations into 2027.